So, Futibatinib is like a special helper that goes after a kind of problem called FGFR2 fusions in cholangiocarcinoma. Its job is to put a stop to something called FGFR signaling.
The tablet form is 4 mg, with a recommended daily dose of 20 mg taken once. It’s packaged in bottles, each with 28 tablets inside.
